Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: A meta-analysis

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 582-586

  Pedrelli, Paola ^a   Iovieno, Nadia ^a,b   Vitali, Mario ^a,c   Tedeschini, Enrico ^a,d   Bentley, Kate H ^a   Papakostas, George I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Antidepressant; major depressive disorder; methadone maintenance therapy; opiateuse disorders; placebo

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; METHADONE; PLACEBO; SERTRALINE;

ARTICLE; COMORBIDITY; DRUG EFFICACY; DYSTHYMIA; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; META ANALYSIS; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); DYSTHYMIC DISORDER; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80052427301     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822c0adf     Document Type: Article

References (40)

1. Nandi A, Beard JR, Galea S. Epidemiologic heterogeneity of common mood and anxiety disorders over the life course in the general population: a systematic review. BMC Psychiatry. 2009;9:31.
2. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127. (Pubitemid 36469860)
3. Rounsaville BJ, Kosten TR,Weissmann MM, et al. A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts. Compr Psychiatry. 1986;27(3):201-210. (Pubitemid 16068713)
4. Rounsaville BJ, Weissman MM, Crits-Christoph K, et al. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39(2):151-156. (Pubitemid 12178987)
5. Strain EC, Stitzer ML, Bigelow GE. Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis. 1991;179(4):215-221.
6. Kosten TR, Gawin FH, Morgan C, et al. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16(3-4):329-336.
7. Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54(1):71-80. (Pubitemid 27044701)
8. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343(26):1942-1950. (Pubitemid 32064789)
9. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009;166(5):599-607.
10. Zetin M, Hoepner CT. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol. 2007;27(3):295-301. (Pubitemid 46763313)
11. Posternak MA, Zimmerman M, Keitner GI, et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry. 2002;159(2):191-200. (Pubitemid 34126894)
12. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469-473. (Pubitemid 34184745)
13. Zimmerman M, Chelminski I, Posternak MA. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis. 2004;192(2):87-94. (Pubitemid 38248899)
14. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15): 1887-1896. (Pubitemid 38509503)
15. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782. (Pubitemid 9064061)
16. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26(1):57-63.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
18. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
19. Guy W. National Institute of Mental Health (U.S.). Psychopharmacology Research Branch., Early Clinical Drug Evaluation Program: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch: Division of Extramural Research Programs; 1976.
20. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840- 1847. (Pubitemid 34303629)
21. Kleber HD, Weissman MM, Rounsaville BJ, et al. Imipramine as treatment for depression in addicts. Arch Gen Psychiatry. 1983;40(6):649-653. (Pubitemid 13094932)
22. Nunes EV, Quitkin FM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry. 1998;55(2):153-160. (Pubitemid 28087601)
23. Carpenter KM, Brooks AC, Vosburg SK, et al. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend. 2004;74(2):123-134. (Pubitemid 38501686)
24. Petrakis I, Carroll KM, Nich C, et al. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend. 1998;50(3):221-226. (Pubitemid 28271639)
25. Kidorf M, Disney ER, King VL, et al. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004;74(2):115-122. (Pubitemid 38501685)
26. Peles E, Schreiber S, Naumovsky Y, et al. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord. 2007;99:213-220. (Pubitemid 46275039)
27. Rosen D, Smith ML, Reynolds III CF. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry. 2008;16(6):488-497.
28. Teesson M, Havard A, Fairbairn S, et al. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend. 2005;78(3):309-315. (Pubitemid 40694053)
29. Brienza RS, Stein MD, Chen MG, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat. 2000;18(4):331-337. (Pubitemid 30254355)
30. Carpentier PJ, Krabbe PFM, van Gogh MT, et al. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict. 2009;18:470-480.
31. Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry. 1986;43(8):733-738. (Pubitemid 16035157)
32. Rounsaville BJ, Kosten TR, Weissman MM, et al. Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study. Arch Gen Psychiatry. 1986;43(8):739-745. (Pubitemid 16035158)
33. McLellan AT, Woody GE, Luborsky L, et al. Increased effectiveness of substance abuse treatment. A prospective study of patient-treatment "matching". J Nerv Ment Dis. 1983;171(10):597-605. (Pubitemid 13017360)
34. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56(10):793-802. (Pubitemid 39539838)
35. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
36. Brown SA, Glasner-Edwards SV, Tate SR, et al. Integrated cognitive behavioral therapy versus twelve-step facilitation therapy for substance-dependent adults with depressive disorders. J Psychoactive Drugs. 2006;38(4):449-460. (Pubitemid 46340090)
37. Brown AR, Evans DM, Miller WI, et al. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol. 1997;5:715-726. (Pubitemid 27439063)
38. Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol. 1977;106(3):203-214. (Pubitemid 8190169)
39. Ferrari A, Coccia CP, Bertolini A, et al. MethadoneVmetabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50(6):551-559.
40. Hamilton SP, Nunes EV, Janal M, et al. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict. 2000;9(1):63-69. (Pubitemid 30155034)